# A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

> **NCT06066138** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced Alveolar Soft Part Sarcoma
- Metastatic Alveolar Soft Part Sarcoma
- Locally Advanced Non Small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer
- Locally Advanced Small Cell Lung Cancer
- Metastatic Small Cell Lung Cancer
- Locally Advanced Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma
- Locally Advanced Melanoma
- Metastatic Melanoma

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT06066138
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-04
- **Primary completion:** 2027-01-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066138, "A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06066138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*